Author Index: W
• UNDERSTANDING DIFFERENCES BETWEEN COGNITIVE AND AFFECTIVE RISK PERCEPTIONS: COMPARING DON'T KNOW RESPONSES
• FIRST IMPRESSIONS: “WHAT DO YOU THINK OF WHEN YOU HEAR THE WORDS SIDE EFFECT?”
• SMOKERS' UNEXPECTED COMMENTS ON CIGARETTE ADDITIVES DURING FOCUS GROUPS EXAMINING BELIEFS ABOUT SMOKING AND GENETICS
• DON'T KNOW RESPONDING TO RISK PERCEPTION MEASURES IN RELATION TO DEFENSIVE PROCESSES
• THE KITCHEN SINK: COMBINING MULTIPLE RISK COMMUNICATION STRATEGIES TO CONVEY MULTIPLE DISEASE RISKS
• FIRST IMPRESSIONS: “WHAT DO YOU THINK OF WHEN YOU HEAR THE WORDS SIDE EFFECT?”
• SMOKERS' UNEXPECTED COMMENTS ON CIGARETTE ADDITIVES DURING FOCUS GROUPS EXAMINING BELIEFS ABOUT SMOKING AND GENETICS
• DON'T KNOW RESPONDING TO RISK PERCEPTION MEASURES IN RELATION TO DEFENSIVE PROCESSES
• THE KITCHEN SINK: COMBINING MULTIPLE RISK COMMUNICATION STRATEGIES TO CONVEY MULTIPLE DISEASE RISKS
• IMPROVING UNDERSTANDING OF DIAGNOSTIC SCREENING TESTS THROUGH SIMULATED EXPERIENCE
• LOOKING IN ALL THE WRONG PLACES: DEFICITS IN INFORMATION SEARCH BEHAVIOR RESULTS IN SUBOPTIMAL HEALTH PLAN SELECTION
• HOW DO PATIENTS INTERPRET VARIABILITY AND SLOPE IN BLOOD PRESSURE DATA VISUALIZATIONS?
• DESIGNING DATA VISUALIZATIONS TO SUPPORT SHARED DECISION MAKING ABOUT BLOOD PRESSURE
• LOOKING IN ALL THE WRONG PLACES: DEFICITS IN INFORMATION SEARCH BEHAVIOR RESULTS IN SUBOPTIMAL HEALTH PLAN SELECTION
• HOW DO PATIENTS INTERPRET VARIABILITY AND SLOPE IN BLOOD PRESSURE DATA VISUALIZATIONS?
• DESIGNING DATA VISUALIZATIONS TO SUPPORT SHARED DECISION MAKING ABOUT BLOOD PRESSURE
• INFECTIOUS DISEASE MODELING INTEREST GROUP MEETING
• COST-EFFECTIVENESS ANALYSIS OF DRUGS FOR CHRONIC HEPATITIS C INFECTION: INFORMING ON LISTING DECISIONS OF INTERFERON-FREE DIRECT-ACTING ANTIVIRAL REGIMENS IN CANADA
• IS VERY EARLY HTA POSSIBLE? A MATHEMATICAL FRAMEWORK OF USING ECONOMIC EVALUATION MODELS TO INFLUENCE THE DIRECTION OF DRUG DISCOVERY
• A SYSTEMATIC REVIEW AND META-ANALYSIS OF HEALTH UTILITIES IN CHRONIC HEPATITIS C PATIENTS
• HEALTH UTILITIES IN CHRONIC HEPATITIS C PATIENTS WITH LATE-STAGE LIVER DISEASE
• COST-EFFECTIVENESS ANALYSIS OF DRUGS FOR CHRONIC HEPATITIS C INFECTION: INFORMING ON LISTING DECISIONS OF INTERFERON-FREE DIRECT-ACTING ANTIVIRAL REGIMENS IN CANADA
• IS VERY EARLY HTA POSSIBLE? A MATHEMATICAL FRAMEWORK OF USING ECONOMIC EVALUATION MODELS TO INFLUENCE THE DIRECTION OF DRUG DISCOVERY
• A SYSTEMATIC REVIEW AND META-ANALYSIS OF HEALTH UTILITIES IN CHRONIC HEPATITIS C PATIENTS
• HEALTH UTILITIES IN CHRONIC HEPATITIS C PATIENTS WITH LATE-STAGE LIVER DISEASE